Etavopivat
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Conditions
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Trial Timeline
Nov 15, 2022 → Jul 15, 2024
NCT ID
NCT05568225About Etavopivat
Etavopivat is a phase 2 stage product being developed by Novo Nordisk for Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R. The current trial status is terminated. This product is registered under clinical trial identifier NCT05568225. Target conditions include Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06581627 | Phase 1 | Completed |
| NCT06433661 | Phase 1 | Completed |
| NCT06336018 | Phase 1 | Completed |
| NCT05725902 | Phase 2 | Active |
| NCT06198712 | Phase 2 | Recruiting |
| NCT05568225 | Phase 2 | Terminated |
Competing Products
10 competing products in Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 77 |
| Benralizumab Arm A + Benralizumab Arm B + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab Arm A + Benralizumab Arm B + Benralizumab Arm C + Placebo | AstraZeneca | Phase 3 | 77 |
| Ruxolitinib | Novartis | Pre-clinical | 23 |
| Ipilimumab | Bristol Myers Squibb | Phase 1/2 | 40 |
| BAY207543 (Bepanthol, Bepantol® Derma Spray) | Bayer | Approved | 82 |
| BAY207543 (Bepanthol, Bepantol® Derma Spray) | Bayer | Approved | 82 |
| triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |
| Chondrogen + Chondrogen + Placebo | Mesoblast | Phase 1/2 | 36 |
| Mesenchymal Stem Cells + Hyaluronan | Mesoblast | Phase 1/2 | 36 |